Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. - Wikidata - wikimedia - TriplyDB

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

http://www.wikidata.org/entity/Q34644962

about

Idiopathic Inflammatory Myopathies: Clinical Approach and Management Treatment of inflammatory myopathy: emerging therapies and therapeutic targets Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies Update in juvenile myositis Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies Biologics in dermatology: an integrated review Idiopathic inflammatory myopathies Rituximab in the treatment of inflammatory myopathies: a review Treatment of primary Sjögren syndrome.Immunotherapies for Immune-Mediated Myopathies: A Current Perspective Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a Treg cell-deficient milieu Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.Idiopathic inflammatory myopathies.Developing a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research.Cutaneous dermatomyositis: an updated review of treatment options and internal associations.Cutaneous dermatomyositis in the era of biologicals.Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.An overview of polymyositis and dermatomyositis.Drugs in induction and treatment of idiopathic inflammatory myopathies Brief report: antisynthetase syndrome-associated myocarditis Anti-signal recognition particle autoantibody ELISA validation and clinical associations.Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.Biologic predictors of clinical improvement in rituximab-treated refractory myositis Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial Increased Risk of Herpes Zoster Following Dermatomyositis and Polymyositis: A Nationwide Population-Based Cohort Study.Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies.Antibody therapy of pediatric B-cell lymphoma From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013 Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.Consensus-based recommendations for the management of juvenile dermatomyositis.Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome.Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.Clinical heterogeneity and outcomes of antisynthetase syndrome.Diagnosis, pathogenesis and treatment of myositis: recent advances.

P2860

Q26744705-BD977CF9-B6B6-4738-822A-333A37898356 Q26796546-5D42104E-4A0D-4403-8F86-33E20D4855C6 Q26798209-4EC2CD7C-FBB9-4D14-9374-BAFA16C9F687 Q26822598-02878E86-8A26-44A1-90B3-EE3BBC663FE8 Q26863125-AD6472FD-214D-458A-ADF8-26ED8850B739 Q27004638-F632C93B-216B-4FD1-ABF7-1F878EA0451B Q27025125-A7A2FAE1-7DCB-43A7-99C8-4282B8B307B6 Q28077745-63F1365E-C749-4876-919C-E5F0C518C1D3 Q30249011-FBE5F693-64A1-48A4-BCB9-060D9028CCAF Q30699742-7CF1D021-A94F-4C68-B6A8-2E87A9547A79 Q33661671-21B71563-958C-4EE6-ABF1-26DA4C4D9299 Q33795594-D0766D24-E53A-4813-966A-EB6A2F43B38D Q33924451-FAE11336-D1F2-47FF-94BF-075B7C519291 Q33962448-D44EB73C-CFF3-4724-BC3E-6AF3BA3B418A Q34349952-826C4F0F-5784-4024-8CA8-91A69FB8115A Q34501531-104806CE-A02E-4E9E-B1BF-E44B6B969153 Q34528042-17A44EAD-F629-40D5-A2B8-B5483063E211 Q34667765-B068A099-CC07-421E-AC09-1BB320DAC4C9 Q35281940-001A21D3-7568-4A49-B4EB-245DB6FE3C50 Q35618761-3C2BD450-2A73-4C1E-9511-30FB34365BBD Q35759167-19DF64F4-0B08-4392-9667-E6C087ABF9F4 Q35767694-C151BB6B-3842-4E7C-92E8-28871FA00929 Q35779841-7BD18A20-5AA5-461B-BF8F-A2FF967B911A Q35833312-0D252417-1DD4-4A82-95A3-1EA081050DF9 Q36196678-3BD2100A-1952-4C70-A18A-4C5CD116B2C2 Q36278027-3A40D23A-2178-4D53-A24D-2F8E4E9E7D31 Q36394613-966277C1-A8D9-4522-88A7-D229FEF81262 Q36484399-08639C16-B335-4AC1-8C23-83DBAF548806 Q36484465-940EC9F0-920F-471E-92FC-ED3BD47CB714 Q36591665-46067988-A967-401C-99C1-146CCBE06CCD Q36732959-AFF8C0D5-5166-4F50-80EC-6DD4A66DFE9C Q37038527-0C47102E-2721-4A9D-8913-439072F3AFBF Q37095730-437C93DD-54E8-46DD-8B50-C0D54BA22A38 Q37368405-04041A1E-4F4B-45CD-8190-78BD2B468929 Q37427265-B3829929-426F-4F16-8766-AE7A2ECF0487 Q37617000-03C37991-777B-4C44-861F-1474A630FFA8 Q37690885-4A8E5352-0157-4BB4-A078-450AD6E70C51 Q37704799-4C0F5C3A-FBC3-45D7-835D-F329AB8008AA Q38116464-FD15526F-D8A1-410A-8D95-E19D3758795B Q38131849-D7ED9862-BAF4-4746-B0B7-577C4488B5E3

P2860

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

http://www.wikidata.org/entity/Q34644962

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@ast

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@en

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@nl

type

label

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@ast

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@en

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@nl

prefLabel

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@ast

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@en

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@nl

P1433

Q34644962-C2E2D914-28DB-44DE-8377-6E979F52C027

P1476

Q34644962-5A9C58E7-7C78-4FAE-A3A4-B00FA454A624

P2093

Q34644962-0D6CC97A-9EB9-4ACB-B0F7-9C8D421896F6

Q34644962-12758E54-F0EB-417F-928A-EDC234C0DB3A

Q34644962-12A1408B-0266-4AFF-B78B-A567C4B225BD

Q34644962-30704EEA-C097-45A9-9BCC-185E735E18DC

Q34644962-42648B06-FFE4-414C-A62E-B444E0D26FE7

Q34644962-44A02B6F-288E-41FD-BC8A-C832E2EE0349

Q34644962-48938844-7539-4F23-A923-497FFB1F751E

Q34644962-5EB0A449-FB24-4246-8CC6-6C0854606220

Q34644962-680A4FEF-B8B7-4B18-A413-9222F124034B

Q34644962-A47F9351-5380-4625-809D-78A3A28450A7

P2860

Q34644962-14A760DE-E53D-4769-BC76-9C7D7F77D1F7

Q34644962-15A686DD-67B6-43E8-A4F0-F8FB5CAE14D0

Q34644962-17C13E59-B044-4165-936C-3D4EA1C619EF

Q34644962-1BAA4B9D-86EB-444D-90B0-C0027CBA7546

Q34644962-313CD1E4-0608-4CBD-8918-0E38B043FCEE

Q34644962-3584FE08-845F-4703-978B-89BF4B9BDA54

Q34644962-4BC967AB-2453-4286-9722-95279A666B55

Q34644962-4BE48431-B284-471C-8FD0-D6B5B182512C

Q34644962-4C3AD5F6-5E84-4784-A3E9-E6B1DB165EB5

Q34644962-56B7B04F-5950-413A-87F2-04CBE6A1CAFB

P304

Q34644962-B4A38B25-27C1-41DD-8179-B29A7380CA57

P31

Q34644962-0E6CFDC9-1B5E-4A82-ABC0-1CECCBD5AC4C

P356

Q34644962-64F0FC33-7862-44CD-8CB7-6DAAB9453502

P433

Q34644962-E39C5E68-57C8-4D50-AC4B-75A7D7423165

P478

Q34644962-669877A4-D762-4055-B997-4ABD7D5596A5

P577

Q34644962-8CC1E192-928D-40CD-AA76-CFBAE74C3AA4

P698

Q34644962-E98152A3-3E5D-49A5-94BF-CFC86A3D690C

P921

Q34644962-14989227-9FEC-4F56-A9AA-F86710D8A304

Q34644962-4B556D3D-9F6C-4556-9A30-D6C65C2BE97C

Q34644962-BE727998-0616-4EED-B5EF-CCDF7AC0B322

P932

Q34644962-C401C784-A12A-4475-BE5F-E8DD67DFDCD9

P356

P1433

Arthritis & Rheumatology

P1476

Rituximab in the treatment of ...... ndomized, placebo-phase trial.

@en

P2093

Ann M Reed

http://www.w3.org/2001/XMLSchema#string

Brian M Feldman

http://www.w3.org/2001/XMLSchema#string

Chester V Oddis

http://www.w3.org/2001/XMLSchema#string

Dana P Ascherman

http://www.w3.org/2001/XMLSchema#string

Diane C Koontz

http://www.w3.org/2001/XMLSchema#string

Frederick W Miller

http://www.w3.org/2001/XMLSchema#string

Howard E Rockette

http://www.w3.org/2001/XMLSchema#string

Lisa G Rider

http://www.w3.org/2001/XMLSchema#string

Marc C Levesque

http://www.w3.org/2001/XMLSchema#string

Michael O Harris-Love

http://www.w3.org/2001/XMLSchema#string

P2860

Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.

Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Polymyositis: an overdiagnosed entity.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.

Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series

Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies.

P304

314-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.37754

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23124935

http://www.w3.org/2001/XMLSchema#string

P921

dermatomyositis

P932

3558563

http://www.w3.org/2001/XMLSchema#string